GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: compound 68 [WO2010002845A2] | HMPL-813 | HMPL813
Compound class:
Synthetic organic
Comment: Epitinib (HMPL-813) is a selective EGFR tyrosine kinase inhibitor that is under investigation for potential to treat solid tumours in China. Epitinib appears to be a 'pseudo' INN. As of July 2021 there had been no submission to the WHO for the INN. The chemical structure is claimed in patent WO2010002845A2 [1].
|
|
|||||||||||||||||||||||||||||||||||
Classification ![]() |
|
| Compound class | Synthetic organic |
IUPAC Name ![]() |
| 4-ethyl-N-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide |
Synonyms ![]() |
| compound 68 [WO2010002845A2] | HMPL-813 | HMPL813 |
Database Links ![]() |
|
| GtoPdb PubChem SID | 442878642 |
| PubChem CID | 59142777 |
| Search Google for chemical match using the InChIKey | DQAZPZIYEOGZAF-UHFFFAOYSA-N |
| Search Google for chemicals with the same backbone | DQAZPZIYEOGZAF |
| UniChem Compound Search for chemical match using the InChIKey | DQAZPZIYEOGZAF-UHFFFAOYSA-N |
| UniChem Connectivity Search for chemical match using the InChIKey | DQAZPZIYEOGZAF-UHFFFAOYSA-N |
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖|
Epitinib (links to external site)
Cat. No. HY-139300 |